About to Re-rate?30 Sep 2025 10:22
Like this bit from article:
Well to me, after successfully raising £6.35m in July to extend its cash runway until H2’26, the business now appears ideally placed to drive substantial shareprice appreciation by monetising its treasure trove of IPR.
Indeed this already seems to be happening, as today
@VericiDx
released ‘in line’ H1’25 results (turnover $1.9m) including 1st revenues from its lead product Tutivia ($1.16m vs $2k LY). With 591 tests ordered compared to 334 for the whole of 2024, across 21 transplant centres, representing 10% of US volumes.
Sure there is still a long way to go, yet this is an enormous $900m addressable market, which is increasingly being serviced by both #VRCI's own in-house sales team, and its strategic partnership with
@thermofisher
Scientific.
Here good commercial progress continues to be made following the licensing of the PTRA/Clarava prognostic to TFS in Q4'23. There remains significant potential from this strong ongoing relationship and the Board expect to recognise further milestone payments, as well as ongoing royalty income.
CEO Sara Barrington commenting: "We have an exciting opportunity to deliver accelerated commercial growth in an approx $900m addressable market… [by fully commercialising our] two validated products. Our laboratories and logistical operations are set up, we have all the required regulatory approvals and reimbursement."